The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure

The metabolic rewiring of cardiomyocytes is a widely accepted hallmark of heart failure (HF). These metabolic changes include a decrease in mitochondrial pyruvate oxidation and an increased export of lactate. We identify the mitochondrial pyruvate carrier (MPC) and the cellular lactate exporter mono...

Full description

Saved in:
Bibliographic Details
Published inCell metabolism Vol. 33; no. 3; pp. 629 - 648.e10
Main Authors Cluntun, Ahmad A., Badolia, Rachit, Lettlova, Sandra, Parnell, K. Mark, Shankar, Thirupura S., Diakos, Nikolaos A., Olson, Kristofor A., Taleb, Iosif, Tatum, Sean M., Berg, Jordan A., Cunningham, Corey N., Van Ry, Tyler, Bott, Alex J., Krokidi, Aspasia Thodou, Fogarty, Sarah, Skedros, Sophia, Swiatek, Wojciech I., Yu, Xuejing, Luo, Bai, Merx, Shannon, Navankasattusas, Sutip, Cox, James E., Ducker, Gregory S., Holland, William L., McKellar, Stephen H., Rutter, Jared, Drakos, Stavros G.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 02.03.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The metabolic rewiring of cardiomyocytes is a widely accepted hallmark of heart failure (HF). These metabolic changes include a decrease in mitochondrial pyruvate oxidation and an increased export of lactate. We identify the mitochondrial pyruvate carrier (MPC) and the cellular lactate exporter monocarboxylate transporter 4 (MCT4) as pivotal nodes in this metabolic axis. We observed that cardiac assist device-induced myocardial recovery in chronic HF patients was coincident with increased myocardial expression of the MPC. Moreover, the genetic ablation of the MPC in cultured cardiomyocytes and in adult murine hearts was sufficient to induce hypertrophy and HF. Conversely, MPC overexpression attenuated drug-induced hypertrophy in a cell-autonomous manner. We also introduced a novel, highly potent MCT4 inhibitor that mitigated hypertrophy in cultured cardiomyocytes and in mice. Together, we find that alteration of the pyruvate-lactate axis is a fundamental and early feature of cardiac hypertrophy and failure. [Display omitted] •Myocardial MPC expression coincides with LVAD-mediated recovery in chronic HF patients•Loss of the MPC in cells or mouse hearts is sufficient to induce hypertrophy and HF•MPC overexpression attenuates drug-induced hypertrophy in a cell-autonomous manner•Inhibition of MCT4 can mitigate hypertrophy in cultured cardiomyocytes and in mice Cluntun et al. identify the pyruvate-lactate axis as a critical node in cardiac homeostasis and health. This axis is maintained by a careful regulation of the disposition of pyruvate, including mitochondrial import and cellular export as lactate. During hypertrophy and heart failure, this balance is disrupted. Regaining this balance by inhibiting MCT4 ameliorated the hypertrophic phenotype.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author Contributions
Conceptualization, A.A.C., R.B., S.N., S.H.M., J.R., and S.G.D.; Methodology, Validation, Formal Analysis, and Investigation, A.A.C., R.B., S.L., K.M.P., T.S.S., N.A.D., K.A.O., I.T., S.M.T., J.A.B., C.N.C., T.V.R., A.J.B., A.T.K., S.F., S.S, W.I.S, X.Y., B.L., S.M., S.N., and J.E.C.; Software, J.A.B.; Resources, K.M.P., W.I.S., X.Y., J.E.C., G.S.D., W.L.H., S.H.M., and S.G.D.; Data Curation, A.A.C., R.B., S.L., I.T. and J.A.B.; Writing - Original Draft, A.A.C., R.B., S.G.D, and J.R.; Writing - Review & Editing, A.A.C., R.B., S.L., S.F., S.N., S.H.M., J.R., and S.G.D.; Visualization, A.A.C., R.B., K.M.P, and J.A.B.; Supervision, J.R., and S.G.D.; Funding Acquisition, S.H.M., J.R., and S.G.D.
ISSN:1550-4131
1932-7420
1932-7420
DOI:10.1016/j.cmet.2020.12.003